

Freeform Search

Database:	US Pre-Grant Publication Full-Text Database
	US Patents Full-Text Database
	US OCR Full-Text Database
	EPO Abstracts Database
	JPO Abstracts Database
	Derwent World Patents Index
	IBM Technical Disclosure Bulletins
Term:	L18 NOT L19
Display:	<input type="text" value="20"/> Documents in Display Format: <input type="text" value="CIT"/> Starting with Number <input type="text" value="1"/>
Generate: <input type="radio"/> Hit List <input checked="" type="radio"/> Hit Count <input type="radio"/> Side by Side <input type="radio"/> Image	

Search

Clear

Interrupt

Search History

DATE: Saturday, December 01, 2007 [Purge Queries](#) [Printable Copy](#) [Create Case](#)

Set Name	Query	Hit Count	Set Name result set
side by side			
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L21</u>	L18 NOT L19	6	<u>L21</u>
<u>L20</u>	L18 NOT L9	0	<u>L20</u>
<u>L19</u>	L16 and ((dispersity or distribution) same ("particle size" or diameter))	8	<u>L19</u>
<u>L18</u>	L17 and ((dispersity or distribution) same ("particle size" or diameter))	14	<u>L18</u>
<u>L17</u>	L14 and (fluticasone or beclomethasone)	143	<u>L17</u>
<u>L16</u>	L15 and (fluticasone or beclomethasone)	98	<u>L16</u>
<u>L15</u>	L12 and ("anti-fungal" or antifungal or fluconazole or itraconazole)	104	<u>L15</u>
<u>L14</u>	L13 and ("anti-fungal" or antifungal or fluconazole or itraconazole)	149	<u>L14</u>
<u>L13</u>	L11 and @ad<20040329	636	<u>L13</u>
<u>L12</u>	L11 and @ad<20030416	462	<u>L12</u>
<u>L11</u>	L10 and (rhinitis or rhinosinusitis)	1169	<u>L11</u>
<u>L10</u>	L9 and (aqueous near6 suspension)	2417	<u>L10</u>
<u>L9</u>	(beclomethasone or mometasone or fluticasone or beconase or flonase)	7005	<u>L9</u>
<i>DB=PGPB,USPT; PLUR=YES; OP=OR</i>			
<u>L8</u>	L7 NOT L6	9	<u>L8</u>
<u>L7</u>	L5 and @ad<20040329	24	<u>L7</u>
<u>L6</u>	L5 and @ad<20030416	15	<u>L6</u>

<u>L5</u>	L4 and (rhinitis or rhinosinusitis)	43	<u>L5</u>
<u>L4</u>	L3 and (aqueous near6 suspension)	205	<u>L4</u>
<u>L3</u>	L2 and (beclomethasone or mometasone or fluticasone or beconase or flonase)	653	<u>L3</u>
<u>L2</u>	(424/46 or 424/489).ccls.	5784	<u>L2</u>
<u>L1</u>	((((((((((Imtiaz Chaudry) AND @pd>20070416) AND @pd>20070420) AND @pd>20070509) AND @pd>20070511) AND @pd>20070516) AND @pd>20070531) AND @pd>20071009) AND @pd>20071109) AND @pd>20071112) AND @pd>20071119	3	<u>L1</u>

END OF SEARCH HISTORY



Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.

Additionally, enter the **first few letters** of the Inventor's First name.

Last Name

First Name

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)

Freeform Search

Database:	US Pre-Grant Publication Full-Text Database US Patents Full-Text Database US OCR Full-Text Database EPO Abstracts Database JPO Abstracts Database Derwent World Patents Index IBM Technical Disclosure Bulletins
Term:	L5 and (rhinitis or sinusitis or rhinosinusitis)
Display:	20 Documents in Display Format: CIT Starting with Number 1
Generate: <input type="radio"/> Hit List <input checked="" type="radio"/> Hit Count <input type="radio"/> Side by Side <input type="radio"/> Image	

Search

Clear

Interrupt

Search History

DATE: Saturday, December 01, 2007
 [Purge Queries](#)
 [Printable Copy](#)
 [Create Case](#)

<u>Set</u> <u>Name</u>	<u>Query</u>	<u>Hit</u> <u>Count</u>	<u>Set</u> <u>Name</u> <small>result set</small>
<small>side by side</small>			
<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; PLUR=YES; OP=OR</i>			
<u>L6</u>	L5 and (rhinitis or sinusitis or rhinosinusitis)	19	<u>L6</u>
<u>L5</u>	L4 and @ad<20030416	101	<u>L5</u>
<u>L4</u>	L3 and ((EDTA or "sodium edetate" or "editic acid" or "citric acid" or "ethylenediamminetetraacetic acid" or "nitrilotriacetic acid") same (aqueous or "propellant-free"))	191	<u>L4</u>
<u>L3</u>	L2 and (EDTA or "sodium edetate" or "editic acid" or "citric acid" or "ethylenediamminetetraacetic acid" or "nitrilotriacetic acid")	553	<u>L3</u>
<u>L2</u>	(nasal\$5 same ("aqueous suspension" or "propellant-free"))	756	<u>L2</u>
<i>DB=USPT; PLUR=YES; OP=OR</i>			
<u>L1</u>	6608054.pn.	1	<u>L1</u>

END OF SEARCH HISTORY

(FILE 'HOME' ENTERED AT 16:51:53 ON 01 DEC 2007)

FILE 'CAPLUS, MEDLINE, USPATFULL' ENTERED AT 16:52:10 ON 01 DEC 2007

L1 13778 S (BECLOMETHASONE OR MOMETASONE OR FLUTICASONE OR BECONASE OR F
L2 114 S L1 (S) (AQUEOUS (5A) SUSPEN?)
L3 37 S L2 NOT PD>20030416
L4 23 S L3 AND (RHINITIS OR RHINOSINUSITIS)
L5 21 DUP REM L4 (2 DUPLICATES REMOVED)
L6 4 S L5 AND ((DIAMETER OR (PARTICLE(W)SIZE)) (P) (DISTRIBUTION OR

=> d que L1

L1 13778 SEA (BECLOMETHASONE OR MOMETASONE OR FLUTICASONE OR BECONASE
OR FLONASE)

=> d que L6

L1 13778 SEA (BECLOMETHASONE OR MOMETASONE OR FLUTICASONE OR BECONASE
OR FLONASE)
L2 114 SEA L1 (S) (AQUEOUS (5A) SUSPEN?)
L3 37 SEA L2 NOT PD>20030416
L4 23 SEA L3 AND (RHINITIS OR RHINOSINUSITIS)
L5 21 DUP REM L4 (2 DUPLICATES REMOVED)
L6 4 SEA L5 AND ((DIAMETER OR (PARTICLE(W) SIZE)) (P) (DISTRIBUTION
OR DISPERSITY))

L6 ANSWER 1 OF 4 USPATFULL on STN

TI Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases

AB A combination of therapeutic agents useful in the treatment of obstructive airways and other inflammatory diseases comprising (i) an adenosine A.sub.2A receptor agonist; and (ii) an anti-cholinergic agent, preferably comprising a member selected from the group consisting of tiotropium and derivatives thereof; the combination being therapeutically effective in the treatment of the diseases when administered by inhalation; as well as to a method of treating the obstructive airways and other inflammatory diseases comprising administering separately, simultaneously or sequentially to the mammal by inhalation a therapeutically effective amount of the combination of therapeutic agents; as well as to a pharmaceutical composition comprising a pharmaceutically acceptable carrier together with the combination of therapeutic agents; as well as to a product containing the compounds of the combination for separate, simultaneous or sequential administration by inhalation to a mammal for the treatment of obstructive airways and other inflammatory diseases. It is preferred that the anti-cholinergic agent component be tiotropium bromide.

ACCESSION NUMBER: 2003:17922 USPATFULL

TITLE: Combination of an adenosine A2A-receptor agonist and tiotropium or a derivative thereof for treating obstructive airways and other inflammatory diseases

INVENTOR(S): Yeadon, Michael, Sandwich, UNITED KINGDOM
Watson, John W., Ledyard, CT, UNITED STATES

PATENT ASSIGNEE(S): Armstrong, Roison Anne, Mystic, CT, UNITED STATES
Boehringer Ingelheim Pharma KG, Ingelheim, GERMANY,
FEDERAL REPUBLIC OF (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003013675	A1	20030116
APPLICATION INFO.:	US 2002-154561	A1	20020524 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-293530P	20010525 (60)
	US 2001-303934P	20010709 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: BOEHRINGER INGELHEIM CORPORATION, 900 RIDGEBURY ROAD,
P. O. BOX 368, RIDGEFIELD, CT, 06877

NUMBER OF CLAIMS: 42

EXEMPLARY CLAIM: 1

LINE COUNT: 4413

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 4 USPATFULL on STN

TI Process for the preparation of suspensions of drug particles for inhalation delivery

AB The invention is directed to a process for the preparation of suspensions of drug particles for inhalation delivery, said process providing particles of optimized particle size and distribution homogeneously dispersed in the carrier. The process, which is also suitable for the preparation of sterile suspensions, includes the step of homogenizing and micronizing the formulation in a turboemulsifier provided with a high-potency turbine, optionally followed by a treatment in a high-pressure homogenizer. A further aspect of the invention is directed to a process for preparing micronized sterile beclomethasone dipropionate by gamma-irradiation.

ACCESSION NUMBER: 2002:268396 USPATFULL

TITLE: Process for the preparation of suspensions of drug particles for inhalation delivery

INVENTOR(S): Bernini, Eva, Parma, ITALY
Malvolti, Chiara, Parma, ITALY
Garzia, Raffaella, Parma, ITALY
Brambilla, Gaetano, Parma, ITALY
Chiesi, Paolo, Parma, ITALY

PATENT ASSIGNEE(S): Chiesi Farmaceutici S.p.A., Parma, ITALY (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6464958	B1	20021015
	WO 2000025746		20000511
APPLICATION INFO.:	US 2001-830884		20010522 (9)
	WO 1999-EP8176		19991028
			20010522 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	IT 1998-MI2364	19981103
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Dees, Jose' G.	
ASSISTANT EXAMINER:	Haghighatian, Mina	
LEGAL REPRESENTATIVE:	Oblon, Spivak, McClelland, Maier & Neustadt, P.C.	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	645	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 4 USPATFULL on STN

TI Aerosols containing beclomethazone nanoparticle dispersions

AB There is disclosed an aerosol comprising droplets of an aqueous dispersion of nanoparticles, said nanoparticles comprising insoluble beclomethazone particles having a surface modifier on the surface thereof. There is also disclosed a method for making the aerosol and methods for treatment using the aerosol.

ACCESSION NUMBER: 1998:47931 USPATFULL

TITLE: Aerosols containing beclomethazone nanoparticle dispersions

INVENTOR(S): Wiedmann, Timothy S., Minneapolis, MN, United States
Wood, Ray W., Ft. Washington, PA, United States
DeCastro, Lan, West Chester, PA, United States

PATENT ASSIGNEE(S): NanoSystems, L.L.C., King of Prussia, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5747001		19980505
APPLICATION INFO.:	US 1995-393973		19950224 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Bawa, Raj		
LEGAL REPRESENTATIVE:	McDermott, Will & Emery		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
LINE COUNT:	895		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 4 USPATFULL on STN

TI Novel liposome composition for the treatment of interstitial lung diseases

AB A non-conventional lipid particle formulation for the sustained release and delivery of steroids into deep lung is disclosed. The formulation provides prolonged release of the drug, improved therapeutic ratio, lower toxicity, reduced systemic side effects, and stability for several months. The formulation is in particular suitable for treatment of interstitial lung diseases.

ACCESSION NUMBER: 91:75536 USPATFULL
TITLE: Novel liposome composition for the treatment of
 interstitial lung diseases
INVENTOR(S): Radhakrishnan, Ramachandran, Fremont, CA, United States
PATENT ASSIGNEE(S): Liposome Technology, Inc., Menlo Park, CA, United
 States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5049389		19910917
APPLICATION INFO.:	US 1989-444738		19891201 (7)
DISCLAIMER DATE:	20070306		
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1988-284158, filed on 14 Dec 1988, now patented, Pat. No. US 4906476, issued on 6 Mar 1990		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Page, Thurman		
ASSISTANT EXAMINER:	Kishore, G. S.		
LEGAL REPRESENTATIVE:	Dehlinger, Peter J., Dolezalova, Hana		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	8 Drawing Figure(s); 8 Drawing Page(s)		